Telogen Effluvium

Burroway, Brandon; Griggs, Jacob; Martínez‐Velasco, María Abril; Tosti, Antonella

doi:10.1007/978-3-030-21555-2_10

Cited by 3 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Therefore, the first-line management is to identify and manage the underlying cause. 6,7 Besides, there are no current US FDA approved treatments, and only a few drugs have demonstrated their efficacy, all being used off-label. 6 These include topical and oral minoxidil, corticosteroids, and CNPDA (caffeine, niacinamide, panthenol, dimethicone and an acrylate polymer).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Zari

2023

SCCAA

View full text Add to dashboard Cite

To assess the effectiveness of adipocyte-derived mesenchymal stem cells-conditioned media (ADSC-CM) formulation in telogen effluvium patients. Methods: A retrospective cohort study was conducted at a dermatology clinic in Jeddah, Saudi Arabia. The study included 50 consecutive patients aged 20-70 years, who were diagnosed with telogen effluvium. All patients received five monthly sessions of the same commercial ADSC-CM formulation, using a standardized application protocol. Pre-and post-intervention changes in trichometry parameters were analyzed. Results: There was a significant increase in mean hair density (up to 29.01 hair/cm 2 ; effect size 0.7-1.0), cumulative hair thickness (up to 2.67 units; effect size 0.7-1.4), and the number of follicular hair units (up to 19.96%; effect size 1.0-1.3) in all scalp regions (p < 0.001), associated with a decrease in mean trichometry-derived Sinclair scale by 0.8-1.3 (p < 0.001). Positive outcomes were observed in 70%-92% of the patients depending on the parameter and scalp region. There was no impact of the patient's age on ADSC-CM efficacy. Conclusion: ADSC-CM was successfully applied as a new treatment option for patients with telogen effluvium. These findings provide another therapeutic and research area for dermatologists to optimize the management of telogen effluvium and reduce its impact on patients.Plain Language Summary: Hair loss can be a distressing experience. Telogen effluvium, a common type of hair loss, was the focus of a study in Saudi Arabia. The goal? To see if a new treatment using a mixture of cytokines, growth factors, and proteins from fat cellderived stem cells (known as ADSC-CM) could help.The researchers worked with 50 people aged between 20 and 70, all of whom were experiencing telogen effluvium. The treatment involved five monthly sessions of the ADSC-CM product. The team measured aspects of hair growth before and after the treatment.What did they find? Encouraging signs! Hair density and thickness significantly improved across the scalp. Additionally, the severity of the hair loss condition was reduced. Between 70% and 92% of people saw positive changes depending on the area of the scalp and the specific measurement.The exciting part is that the age of the person did not affect how well the treatment worked. This suggests it could benefit a wide range of people.In a nutshell, this study suggests ADSC-CM may be a new and effective way to help people experiencing telogen effluvium. More research is needed, but it is a promising avenue for dermatologists to explore and could potentially help reduce the impact of hair loss on people's lives.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Zari

2023

SCCAA

View full text Add to dashboard Cite

show abstract

“…TE is caused by an alteration of the carefully regulated hair follicle cycle involving the anagen, catagen, and telogen phases. Often, a trigger induces premature transition or duration of phases 9 . Acute TE is self‐limited while chronic TE persists greater than 6 months 10 .…”

Section: Introductionmentioning

confidence: 99%

“…Often, a trigger induces premature transition or duration of phases. 9 Acute TE is self-limited while chronic TE persists greater than 6 months. 10 Initial evaluation includes the attempt to identify an underlying trigger.…”

Section: Introductionmentioning

confidence: 99%

Etiology, management, and outcomes of pediatric telogen effluvium: A single‐center study in the United States

Chen

Strazzulla

Asbeck

et al. 2022

Pediatric Dermatology

View full text Add to dashboard Cite

Background/Objectives: Telogen effluvium (TE) is a diffuse, rapidly occurring non-scarring alopecia that can be a significant source of distress for patients and caregivers. To date, the disorder has not been extensively studied in a US pediatric patient population. This study aims to characterize the epidemiology, management, and disease course of pediatric TE.Methods: A retrospective single-center analysis was conducted at the University of Miami including pediatric medical records from 2009 to 2021 with at least one clinic visit coded with the diagnosis of TE.Results: 76 patients presented with a wide range of age at onset and hair loss duration. 67% of patients (n = 51) had an identified trigger, the most common being emotional stress and acute febrile illness, followed by nutritional deficiencies (specifically iron, ferritin, and vitamin D). Observation was the most common therapeutic approach. Of patients who had a follow-up evaluation (39%), different treatments resulted in similar rates of improvement. Conclusions:The results of this study demonstrate the variability in potential TE triggers, physical exam findings, and management in children, similar to what is currently observed and practiced in adult patients. Appropriate work-up for common triggers should be included during the initial visit. Greater evidence-based treatment approaches are needed for pediatric TE.

show abstract

Changes in dermatological complaints among healthcare professionals during the COVID-19 outbreak in Turkey

Metin

Turan

Utlu

2020

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

From April 5th to 12th, 2020, between the 25th and 32nd days after the first COVID-19 case in Turkey, a self-administered online questionnaire (SurveyMonkey®) consisting of 90 questions was conducted for doctors and nurses that voluntarily participated in the study. We aimed to reduce the risk of bias in the questions posed to the participants by carrying out this retrospective study in the early phase of the COVID-19 outbreak. The first part of the questionnaire examined subjects such as demographic characteristics, occupational and institutional information, medical history,

show abstract

Telogen Effluvium

Cited by 3 publications

References 38 publications

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Etiology, management, and outcomes of pediatric telogen effluvium: A single‐center study in the United States

Changes in dermatological complaints among healthcare professionals during the COVID-19 outbreak in Turkey

Contact Info

Product

Resources

About